NexTel Medical Corp. Acquires JumpstartRx and NueVistraMed to Expand Telehealth Operations

NexTel Medical Corp. announced on Tuesday that it has signed definitive purchase agreements to acquire both JumpstartRx and NueVistraMed. These acquisitions aim to expand the company’s existing telehealth operations and accelerate the commercialization of its proprietary product, Maxasome.

The agreements integrate the infrastructure and resources of JumpstartRx and NueVistraMed into NexTel Medical Corp.’s current business model. By incorporating these entities, the company intends to increase its reach within the telehealth market while streamlining the rollout of Maxasome. NexTel Medical Corp. finalized these transactions on June 2, 2026, marking a shift in the company’s operational strategy as it seeks to scale its service offerings and product distribution.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI